Keymed, Biosciences

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Veröffentlicht: 07.08.2025 um 18:09 Uhr, prnewswire.co.uk

Keymed China

View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-long-term-efficacy-and-safety-data-from-a-phase-iii-clinical-trial-of-stapokibart-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-302161407.html

en | boerse | 67921574 |